Next Article in Journal
Non-Steroidal Anti-Inflammatory Drugs, Variation in Inflammatory Genes, and Aggressive Prostate Cancer
Next Article in Special Issue
Endocannabinoids and Human Sperm Cells
Previous Article in Journal
Future Trends in the Pharmacogenomics of Brain Disorders and Dementia: Influence of APOE and CYP2D6 Variants
Previous Article in Special Issue
Tissue Engineering of Cartilage; Can Cannabinoids Help?
Article Menu

Export Article

Open AccessReview
Pharmaceuticals 2010, 3(10), 3101-3126;

Endocannabinoids and Schizophrenia

Centre de Recherche Fernand-Seguin, Department of Psychiatry, University of Montreal, 7331 Hochelaga, Montreal, Quebec, H1N 3V2, Canada
Author to whom correspondence should be addressed.
Received: 10 September 2010 / Accepted: 25 September 2010 / Published: 8 October 2010
(This article belongs to the Special Issue Cannabinoids)
Full-Text   |   PDF [183 KB, uploaded 8 October 2010]


The endocannabinoids anandamide and 2-arachydonoylglycerol (2-AG) are lipids naturally derived from membrane precursors which bind cannabinoid receptors (CB1, CB2). This endocannabinoid system is disturbed in schizophrenia. Indeed, there seems to be an association between schizophrenia and polymorphisms of the CB1 receptor gene. Moreover, CB1 receptors are found in higher density in the prefrontal cortex, hippocampus and basal ganglia of patients with schizophrenia. Similarly, anandamide levels are increased in the cerebrospinal fluid (CSF) and in the serum of schizophrenia patients, including during the prodromal state, suggesting that they may play a protective role in psychosis homeostasis. Future studies are needed to further explore the role of the endocannabinoid system in the pathophysiology of schizophrenia. View Full-Text
Keywords: endocannabinoids; schizophrenia; cannabis; drug abuse; metabolism endocannabinoids; schizophrenia; cannabis; drug abuse; metabolism
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

MDPI and ACS Style

Desfossés, J.; Stip, E.; Bentaleb, L.A.; Potvin, S. Endocannabinoids and Schizophrenia. Pharmaceuticals 2010, 3, 3101-3126.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top